Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk

Aug 28 (Reuters) - Takeda Pharmaceuticals and Eli Lilly & Co lost a bid to overthrow a combined $9 billion punitive-damage award by a U.S. jury for hiding cancer risks associated with their Actos diabetes drug, according to a court ruling.